← FDA DRUG APPROVALS

FDA ANDA · ANDA214202

METHYLPHENIDATE HYDROCHLORIDE

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA214202
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE, CHEWABLE
MARKETING STATUS
None (Tentative Approval)

Products

METHYLPHENIDATE HYDROCHLORIDENone (Tentative Approval)
METHYLPHENIDATE HYDROCHLORIDE 40MG · TABLET, EXTENDED RELEASE, CHEWABLE · ORAL
METHYLPHENIDATE HYDROCHLORIDENone (Tentative Approval)
METHYLPHENIDATE HYDROCHLORIDE 20MG · TABLET, EXTENDED RELEASE, CHEWABLE · ORAL
METHYLPHENIDATE HYDROCHLORIDENone (Tentative Approval)
METHYLPHENIDATE HYDROCHLORIDE 30MG · TABLET, EXTENDED RELEASE, CHEWABLE · ORAL

Approval history

2023-02-07UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →